New York 2025 Session Status: Introduced

A10521 — Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state

Last action — In Assembly Committee

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Assembly
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Assembly. Introduced March 06, 2026. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Prognosis

Not enough signal yet

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.

Bill Text

How this bill changes current law

1 change Share ↗

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

This bill amends 1 section(s) of the New York Consolidated Laws: Section 2500-a of the public health law.

  • Section 2500-a of the public health law

    (l) Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). (m) Mucopolysaccharidosis type IVA (MPS IVA). (n) Mucopolysaccharidosis type VI (MPS VI). (o) Mucopolysaccharidosis type VII (MPS VII). (p) Fabry. 4. The commissioner shall ensure tests are made available for all diseases and conditions designated pursuant to paragraphs (l), (m), (n), (o) and (p) of subdivision one of this section within twelve months of the effective date of such paragraphs. italics

    amended

Action History

  1. PRINT NUMBER 10521A

  2. AMEND AND RECOMMIT TO HEALTH

  3. REFERRED TO HEALTH

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 218 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (218)

218 members have not signed on to this bill.

Show all 218 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does A10521 do?
Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.
Who sponsors A10521?
A10521 is sponsored by Andrew Hevesi.
What is the current status of A10521?
This bill has been introduced in the Assembly. Introduced March 06, 2026. It must pass committee before a floor vote.
Where can I track A10521?
Track A10521 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on A10521

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of A10521

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →